Drug Development
FDA approves Orchard’s Lenmeldy gene therapy for MLD
Lenmeldy utilises the genetically modified haematopoietic stem cells of the patient to halt disease progression.
Lenmeldy utilises the genetically modified haematopoietic stem cells of the patient to halt disease progression.